Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, Dicks-Mireaux
C, Phillips A, Vos A and Plaschkes J (2000) Pretreatment prognostic factors for
children with hepatoblastoma -results from the International Society of Paediatric
Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 36, 1418–1425.
Buendia MA (2014) Unravelling the genetics of hepatoblastoma: few mutations,
what else? J Hepatol 61, 1202–1204.
Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A,
Balakrishnan A, Semeraro M, Gresh L, et al (2008) Hepatic stem-like phenotype
and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver
cancer. Canc Cell 14, 471–484.
Cairo S, Armengol C, Maibach R, Häberle B, Becker K, Carrillo-Reixach J,
Guettier C, Vokuhl C, Schmid I, Buendia MA, et al (2020) A combined clinical
and biological risk classification improves prediction of outcome in hepatoblastoma
patients. Eur J Cancer 141, 30–39.
Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sàbat M, AbrilFornaguera J, Akers N, Sala M, Ragull S, Arnal M, et al (2020) Epigenetic
footprint enables molecular risk stratification of hepatoblastoma with clinical
implications. J Hepatol 73, 328–341.
Cui X, Liu B, Zheng S, Dong K, Dong Rui (2016) Genome-wide analysis of DNA
methylation in hepatoblastoma tissues. Oncol Lett 12, 1529–1534.
Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krallo M, Maibach R,
Rinaldi E, Feng Y, Aronson D, Malogolowkin M, et al (2016) The children’s hepatic
tumors international collaboration (CHIC): novel global rare tumor database yields
new prognostic factors in hepatoblastoma and becomes a research model. Eur J
Cancer 52, 92–101.
40
Eichenmüller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Häberle B,
Cairo S, Leuschner I, von Schweinitz D, Strom TM, et al (2014) The genomic
landscape of hepatoblastoma and their progenies with HCC-like features. J
Hepatol 61, 1312–1320.
Gröbner SN, Worest BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva
VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, et al (2018)
The landscape of genomic alterations across childhood cancers. Nature 559, E10.
Haeberle B, Schweinitz DV (2012) Treatment of hepatoblastoma in the German
cooperative pediatric liver tumor studies. Front Biosci (Elite Ed) 4, 493–498.
Hishiki T, Matsunaga T, Sasaki F, Yano M, Ida K, Horie H, Kondo S, Watanabe K,
Oue T, Tajiri T, et al (2011) Outcome of hepatoblastomas treated using the
Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from
the JPLT. Pediatr Surg Int 27, 1–8.
Hiyama E, Hishiki T, Watanabe K, Ida K, Ueda Y, Kurihara S, Yano M, Hoshino K,
Yokoi A, Takama Y, et al (2020) Outcome and late complications of
hepatoblastomas treated using the Japanese Study Group for Pediatric Liver
Tumor 2 protocol. J Clin Oncol 38, 2488–2498.
Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H,
Horie H, Ohnuma N, Nakagawara A, et al (2008) The methylation status of
RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in
hepatoblastoma patients. Int J Cancer 123, 1117–1125.
Honda S, Miyagi H, Suzuki H, Minato M, Haruta M, Kaneko Y, Hatanaka KC,
Hiyama E, Kamijo T, Okada T, et al (2013) RASSF1A methylation indicates a poor
prognosis in hepatoblastoma patients. Pediatr Surg Int 29, 1147–1152.
Honda S, Minato M, Suzuki H, Fujiyoshi M, Miyagi H, Haruta M, Kaneko Y,
Hatanaka KC, Hiyama E, Kamijo T, et al (2016) Clinical prognostic value of DNA
methylation in hepatoblastoma: four novel tumor suppressor candidates. Cancer
Sci 107, 812–819.
41
Hooks KB, Audoux J, Fazli H, Lesjean S, Ernault T, Dugot-Senant N, LesteLasserre T, Hagedorn M, Rousseau B, Danet C, et al (2018) New insights into
diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology 68,
89–102.
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for
medical statistics. Bone Marrow Transplant 48, 452–458.
Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck
J, Herman JG, Neste LV, et al (2018) Analysis of DNA methylation in cancer:
location revisited. Nat Rev Clin Oncol 15, 459–466.
Klustein M, Nejman D, Greenfield R, Cedar H (2016) DNA methylation in cancer
and aging. Cancer Res 76, 3446–3450.
London WB, Castel V, Monclair T, Ambros PF, Pearson A, Cohn SL, Berthold F,
Nakagawara A, Ladenstein RL, Iehara T, et al (2011) Clinical and biologic features
predictive of survival after relapse of neuroblastoma: a report from the
international neuroblastoma risk group project. J Clin Oncol 29, 3286–3292.
Malogolowkin MH, Katzenstein H, Krailo MD, Chen Z, Bowman L, Reynolds M,
Finegold M, Greffe B, Rowland J, Newman K, et al (2006) Intensified platinum
therapy is an ineffective strategy for improving outcome in pediatric patients with
advanced hepatoblastoma. J Clin Oncol 24, 2879–2884.
Maschietto M, Rodrigues TC, Kashiwabara AY, de Araujo ÉSS, Marques Aguiar
TF, da Costa CML, da Cunha IW, dos Reis Vasques L, Cypriano M, Brentani H, et
al (2016) DNA methylation landscape of hepatoblastomas reveals arrest at early
stages of liver differentiation and cancer-related alterations. Oncotarget 58, 97871–
97889.
McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS (2006) Maternal
and infant birth characteristics and hepatoblastoma. Am J Epidemiol 163, 818–
828.
42
Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, Aronson
DC, Malogolowkin MH, Perilongo G, von Schweinitz D, et al (2017) Risk-stratified
staging in paediatric hepatoblastoma: a unified analysis from the Children’s
Hepatic tumors International Collaboration. Lancet Oncol 18, 122–131.
Monclair T, Brodeur GM, Ambros PF, Brise HJ, Cecchetto G, Holmes K, Kaneko
M, London WB, Matthay KK, Nuchtern JG, et al (2009) The international
neuroblastoma risk group (INRG) staging system : an INRG task force report. J
Clin Oncol 27, 298–303.
Murphy SK, Huang Z, Hoyo C (2012) Differentially methylated regions of
imprinted genes in prenatal, perinatal and postnatal human tissues. PLOS ONE
7, e40924.
Nagae G, Yamamoto S, Fujita M, Fujita T, Nonaka A, Umeda T, Fukuda S,
Tatsuno K, Maejima K, Hayashi A, et al (2021) Genetic and epigenetic basis of
hepatoblastoma diversity. Nat Commun 12, 5423.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo
B, Zsiros J, Roebuck D, Zimmermann A, et al (2009) Cisplatin versus cisplatin plus
doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361, 1662–1670.
Sumazin P, Chen Y, Treviño LR, Sarabia SF, Hampton OA, Patel K, Mistretta M,
Zorman B, Thompson P, Heczey A, et al (2017) Genomic analysis of
hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology
65, 104–121.
Spector LG, Birch J (2012) The epidemiology of hepatoblastoma. Pediatr Blood
Cancer 59, 776–779.
Tost J, Dunker J, Gut IG (2003) Analysis and quantification of multiple
methylation variable positions in CpG islands by pyrosequencing. Biotechiniques
35, 152–156.
Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, Hiyama
43
E, Czauderna P, Roebuck DJ and Tiao GM (2018) 2017 PRETEXT: radiologic
staging system for primary hepatic malignancies of childhood revised for the
Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 48, 536–
554.
Ushijima T, Okochi-Takada E (2005) Aberrant methylations in cancer cells: where
do they come from? Cancer Sci 96, 206–211.
von Schweinitz D (2012) Hepatoblastoma: recent developments in research and
treatment. Semin Pediatr Surg 21, 21–30.
Zhong Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF (2021) Molecular
mechanisms of hepatoblastoma. Semin Liver Dis 41, 28–41.
44
...
論文の公開元へ
